Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol 2012;61:826-33.
Procopio, Giuseppe
Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol 2012;61:826-33. [electronic resource] - European urology Jul 2012 - e5-6; author reply e7-8 p. digital
Publication Type: Letter; Comment
1873-7560
10.1016/j.eururo.2012.03.048 doi
Antineoplastic Agents--therapeutic use
Carcinoma, Renal Cell--drug therapy
Humans
Kidney Neoplasms--drug therapy
Molecular Targeted Therapy
Protein Kinase Inhibitors--therapeutic use
Sirolimus--analogs & derivatives
TOR Serine-Threonine Kinases--antagonists & inhibitors
Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol 2012;61:826-33. [electronic resource] - European urology Jul 2012 - e5-6; author reply e7-8 p. digital
Publication Type: Letter; Comment
1873-7560
10.1016/j.eururo.2012.03.048 doi
Antineoplastic Agents--therapeutic use
Carcinoma, Renal Cell--drug therapy
Humans
Kidney Neoplasms--drug therapy
Molecular Targeted Therapy
Protein Kinase Inhibitors--therapeutic use
Sirolimus--analogs & derivatives
TOR Serine-Threonine Kinases--antagonists & inhibitors